Ads
related to: daratumumab maintenance for myeloma
Search results
Results from the WOW.Com Content Network
Multiple myeloma cells with higher levels of CD38 show greater daratumumab-mediated cell lysis than cells with low CD38 expression. [28] CD38 enzyme results in the formation of the immunosuppressive substance adenosine , so eliminating CD38-containing cells increases the ability of the immune system to eliminate cancer.
[113] The addition of subcutaneous daratumumab to induction and consolidation therapy with bortezomib, lenalidomide, and dexamethasone, and to lenalidomide maintenance therapy, conferred improved progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. [114]
Efficacy of daratumumab and hyaluronidase-fihj in combination with VMP (D-VMP) was evaluated in a single-arm cohort of the PLEIADES trial (NCT03412565), a multi-cohort, open‑label trial. [2] Eligible participants were required to have newly diagnosed multiple myeloma and were ineligible for transplant. [2]
Malignant melanoma of the extremities, multiple myeloma, conditioning treatment before haemopoietic stem cell transplant. Myelosuppression, pulmonary fibrosis and pneumonitis (uncommon), skin necrosis (uncommon), anaphylaxis, hepatic sinusoidal obstruction syndrome and SIADH. Secondary malignancies. [16] Streptozotocin: IV, PO: Alkylates DNA.
Daratumumab [1] Janssen Biotech: multiple myeloma: Nivolumab [1] Bristol-Myers Squibb: advanced renal cell carcinoma: Elotuzumab [1] Bristol-Myers Squibb: multiple myeloma: Sebelipase alfa [1] Alexion Pharmaceuticals: lysosomal acid lipase deficiency: Alectinib [1] Hoffmann-La Roche: ALK-mutated NSCLC: Pembrolizumab [1] Merck Sharp & Dohme ...
"For context, indirect costs, which cover expenses like facility maintenance, utilities, and administrative support, are additive to direct research expenses (i.e., researcher wages), typically at ...
Ads
related to: daratumumab maintenance for myeloma